Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Liu, Jianmin1; * | Liu, Beibei1 | Guo, Yuanyuan | Chen, Zhijun | Sun, Wei | Gao, Wuyue | Wu, Hongliang | Wang, Yan
Affiliations: Department of Urology, First Affiliated Hospital of Bengbu Medical College, Anhui, China
Correspondence: [*] Corresponding author: Jianmin Liu, Department of Urology, First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu 233000, Anhui, China. Tel.: +86 138 65038855; Fax: +86 138 65038855; E-mail: liujianminah@163.com.
Note: [1] Jianmin Liu and Beibei Liu worked equally on the manuscript.
Abstract: BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the most aggressive form of renal cell carcinoma (RCC). OBJECTIVE: This study was aimed to identify the differentially expressed miRNAs and target genes in CCRCC. METHODS: The miRNA and mRNA next-generation sequencing data were downloaded from The Cancer Genome Atlas (TCGA) dataset. Differential expression analysis was performed, followed by correlation analysis of miRNA-mRNA. Functional enrichment and survival analysis was also performed. RESULTS: Seven hundred and eighty-seven patients with CCRCC from TCGA data portal were included in this study. A total of 52 differentially expressed miRNAs were identified in CCRCC. Then 2361 differentially expressed genes (DEGs) were identified. Prediction analysis and correlation analysis revealed that 89 miRNA-mRNA pairs were not only predicted by algorithms but also had a significant inverse relationship. Several differentially expressed miRNAs such as hsa-mir-501 and their target genes including AK1, SLC25A15 and PCDHGC3 had a significant prognostic value for CCRCC patients. CONCLUSIONS: Alterations of differentially expressed miRNAs and target genes may be involved in the development of CCRCC and can be considered as the prognostic markers for CCRCC.
Keywords: Clear cell renal cell carcinoma, differentially expressed miRNAs, targets, survivability
DOI: 10.3233/CBM-181558
Journal: Cancer Biomarkers, vol. 23, no. 2, pp. 279-290, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl